Competitive AdvantageVyvgart’s favorable safety will remain a key differentiator, supporting its continued use as the first biologic of choice.
Market PerformanceVisible Alpha consensus estimates project significant sales growth for Vyvgart in CIDP, representing a substantial portion of long-term consensus sales for Argenx.
Product LaunchVyvgart Hytrulo was approved for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), which is viewed as the second potential blockbuster opportunity for the Vyvgart franchise.